Clovis Oncology Inc
NASDAQ:CLVS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Clovis Oncology Inc
Accounts Receivables
Clovis Oncology Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Clovis Oncology Inc
NASDAQ:CLVS
|
Accounts Receivables
$26.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
206%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Clovis Oncology Inc's Accounts Receivables?
Accounts Receivables
26.9m
USD
Based on the financial report for Dec 31, 2021, Clovis Oncology Inc's Accounts Receivables amounts to 26.9m USD.
What is Clovis Oncology Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
206%
Over the last year, the Accounts Receivables growth was 1%. The average annual Accounts Receivables growth rates for Clovis Oncology Inc have been 28% over the past three years , 206% over the past five years .